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We evaluated safety and feasibility of the transvenous 
limb perfusion gene delivery method in muscular dystro-
phy. A dose escalation study of single limb perfusion with 
0.9% saline starting with 5% of limb volume was car-
ried out in adults with muscular dystrophies under intra-
venous analgesia/anesthesia. Cardiac, vascular, renal, 
muscle, and nerve functions were monitored. A tourni-
quet was placed above the knee with inflated pressure 
of 310 mm Hg. Infusion was carried out with a clinically 
approved infuser via an intravenous catheter inserted in 
the saphenous vein with a goal infusion rate of 80 ml/
minute. Infusion volume was escalated stepwise to 20% 
limb volume in seven subjects. No subject complained of 
any post procedure pain other than due to needle punc-
tures. Safety warning boundaries were exceeded only for 
transient depression of limb tissue oximetry and transient 
elevation of muscle compartment pressures; these were 
not associated with nerve, muscle, or vascular damage. 
Muscle magnetic resonant imaging (MRI) demonstrated 
fluid accumulation in muscles of the perfused lower 
extremity. High-pressure retrograde transvenous limb 
perfusion with saline up to 20% of limb volume at above 
infusion parameters is safe and feasible in adult human 
muscular dystrophy. This study will serve as a basis for 
future gene transfer clinical trials.
Received 24 May 2011; accepted 10 June 2011; published online  
19 July 2011. doi:10.1038/mt.2011.137
IntroductIon
Muscular dystrophies are a heterogeneous group of inherited 
disorders characterized by progressive muscle degeneration. No 
treatments have been shown to halt or reverse disease progres-
sion, despite substantial progress in understanding the genetic 
and molecular bases of these diseases.1 A variety of therapeu-
tic options are in development. These include stem cell transfer 
and gene transfer or gene regulation using both viral vectors and 
nonviral delivery of plasmids, oligonucleotides, and RNAs. In 
human studies of muscular dystrophy, delivery of these therapeu-
tic macromolecules to skeletal muscles has been limited to direct 
intramuscular injection.2–4 In experimental animals, high-pressure 
hydrodynamic retrograde transvenous limb perfusion has been 
successfully used to regionally deliver nucleic acids into skeletal 
muscles with subsequent protein expression.5–11 However, trans-
lating this promising gene delivery technique to human muscular 
dystrophy requires solving multiple logistical problems separate 
from the specific therapeutic agent, including vascular access, 
larger infusion volumes, and analgesia as well as safety and toler-
ability. To address these issues, we conducted a dose escalation 
study of high-pressure transvenous perfusion with 0.9% saline in 
the lower extremities of adult patients with muscular dystrophy.
results
Seven subjects, aged 21–38 years, were studied. Five were female and 
two were male. Two had limb-girdle muscular dystrophy (LGMD) 
2A, two had Emery-Dreifuss muscular dystrophy (EDMD) and 
one each had autosomal recessive LGMD, autosomal dominant 
LGMD and Becker muscular dystrophy. Subject 05, who received 
20% limb perfusion, had prolonged elevated compartment pres-
sures (details below) and the dose escalation was stopped at this 
level. Two subsequent subjects (06 and 07) received 20% limb per-
fusion and magnetic resonant imaging (MRI) studies to assess the 
efficacy and distribution of fluid delivery to muscles.
the perfusion procedure
Perfusion. Table 1 details the specific perfusion parameters. All 
subjects had visible limb volume expansion, firmness to touch, 
and enlargement of mid-calf circumference (Figure 1). There 
was no cardiac dysfunction or signs of systemic fluid overload 
as measured by echocardiogram, electrocardiogram, heart rate, 
respiratory rate, or cutaneous oxygen saturation. Subject 01 was 
the only patient who did not receive deep sedation, intravenous 
analgesia/anesthesia (IVA), thus she was conscious during the 
perfusion (~4 minutes). She commented that “the perfusion 
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was quite uncomfortable, but tolerable”. The remaining subjects 
(02–07) received IVA without need for intubation. None reported 
discomfort or remembered the perfusion after recovering from 
anesthesia (~10–15 minutes postperfusion). Three subjects com-
mented that they felt the perfused leg was little “tight” up to 1–2 
hours postperfusion. Subject 05 had petechiae under and just 
 below the tourniquet site which resolved by 3 days at the post-
perfusion visit. Although the original plan was to monitor each 
subject for up to 24 hours, all seven subjects had returned to base-
line within 4 hours postperfusion requiring only acetaminophen 
or ibuprofen for pain.
Compartment pressure and tissue oxygen saturation moni-
toring. The first three subjects (5–10% of limb volume) did not 
have elevated compartment pressures. Subjects 04–07 had vari-
able  degree of elevation of compartment pressures. Compartment 
pressures return below the safety cut-off of 35 mm Hg within 
10 minutes postperfusion in all subjects other than subject 05. 
Subject 05 (20% limb volume) had persistently elevated compart-
ment pressures above 35 mm Hg with times to recovery below this 
value of 80, 30, and 10 minutes for the lateral, posterior, and an-
terior compartments respectively. During this time, tissue oxygen 
saturation was not reduced and she reported no pain.
During perfusion, subjects 06 and 07 (both 20% limb vol-
ume) showed peak compartment pressures of 155 and 144 mm Hg 
respectively. Pressures started to decrease immediately after the 
perfusion and returned to normal within 10 minutes (Figure 2a). 
Limb tissue oxygen saturation measurements showed a marked 
decline at the end of the perfusion, but rapidly recovered after tour-
niquet release and then rebounded above baseline (Figure 2b).
Preperfusion and postperfusion studies
None of the postperfusion assessments showed any detectable 
injuries related to perfusion. All subjects returned to baseline 
except for healing needle puncture sites at the postperfusion visit 
and all subjects have had telephone follow-up within 2 weeks of 
postperfusion. There were no reported problems in the perfused 
leg. No serious adverse events occurred during this study.
Laboratory studies. The range of fluctuation in serum creatine 
kinase (CK) was consistent with normal variation described in 
muscular dystrophies attributed to normal activity.12,13 Subjects 02 
and 06 each had one occasion when a potassium level was more 
than 0.5 mmol/l higher than baseline. Each was a difficult blood 
draw and there were no associated electrocardiogram changes. 
The levels were within normal limits on repeated testing within 
ten minutes and were attributed to a partially hemolyzed blood 
samples.
Venous and arterial Doppler study. Subject 03 had pre-existing 
venous insufficiency that did not worsen (Supplementary Table 
S1). All other subjects had normal venous and arterial studies 
preperfusion and postperfusion.
Muscle strength test and timed walk. There was no decrease 
in the distance of the timed walk (Supplementary Table S1). 
Subject 03 had decreased muscle strength bilaterally, 54–60% 
decline in hip extension and hip adduction in the perfused leg 
(Supplementary Table S1) and 57–65% decline in the control 
leg (control leg data was not included in Supplementary Table 
S1). We believe that this was probably due to generalized fatigue 
as the postperfusion study was done in the afternoon versus in 
the morning for the preperfusion study. Subject 07 also had a 
40% decrease of muscle strength in hip flexion in the perfused 
leg and a 34% decrease of ankle dorsi-flexion (Supplementary 
Table S1). The decrease in strength occurred in both legs with 
the biggest decrease in hip flexion which could not be directly 
affected by this perfusion procedure as tourniquet placement was 










Figure 1 Photographs of subject 05.


















01 5 4.9 245 310 290 18 60 4
02 5 4 200 310 300 20 67 3
03 10 7 700 310 300 18 70 10
04 15 6.5 975 310 295 18 80 12
05 20 3.5 700 310 300 18 63 11
06 20 3.4 680 310 300 20 62 11
07 20 4 801 310 295 18 80 10
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Neurography. Study values were all within normal reference 
values. Subject 07 had a 22–23% reduction in compound motor 
action potential (CMAP) amplitudes of peroneal nerve in the per-
fused leg. (Supplementary Table S1), this magnitude of changes 
in peroneal CMAP can be observed simply due to differences in 
electrode placement.14,15
MrI studies
At baseline, subjects 06 and 07 had variable patterns of low signal 
intensity on T2-weighted fat-saturation (T2FS) images and high 
signal intensity on the T2 weighted images as expected for fatty 
degeneration. Postperfusion MRI studies were started 30 minutes 
after perfusion was stopped. Figure 3 shows examples of MRI stud-
ies in subjects 06. Subject 06 had a combined muscle mass volume 
expansion of 20% (630 ml preperfusion to 757 ml postperfusion) 
and 07 had an expansion of 19% (780 ml preperfusion to 929 ml 
postperfusion) by muscle manual segmentation analysis in the 
segmented muscles. Figure 4a shows the percent postperfusion 
volumetric change of individual muscle groups, identified by their 
compartment location. The normalized T2FS intensity was also 
markedly increased postperfusion, especially in the muscle groups 
in posterior compartments reflecting increased water content 
(Figure 4b). The volume expansion and fluid signal (T2FS inten-
sity) increase in postperfusion MRI studies further confirmed the 
fluid entry into muscles in the perfused limb segment.
dIscussIon
Our study demonstrates that it is safe and feasible to perform high-
pressure transvenous perfusion with 0.9% saline up to 20% of limb 
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Figure 2 compartment pressure and limb tissue oxygen saturation monitoring in subject 06. (a) Continuous compartment pressure monitor-
ing. Note that the compartment pressure peaked at the end of perfusion and started to recover after the perfusion stopped while tourniquet was still 
inflated for 1 minute. The pressures rapidly recovered once the tourniquet was deflated. (b) continuous INVOS tissue oxygen saturation monitoring. 
The device has a lower reading limit of 15%. Note the rapid recovery to baseline was within 5 minutes postperfusion.
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dystrophy. This study used lower cuff pressures (310 mm Hg ver-
sus 450–700 mm Hg in primate) and lower limb volumes (20% 
versus 35–45% in primate) than in nonhuman primate studies,9,16 
but achieved comparable peak tissue/compartment pressures dur-
ing the perfusion (155 mm Hg versus 175 mm Hg in primate). This 
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Figure 4 Postperfusion percent changes of muscle groups in subjects 06 and 07. (a) volumetric changes. (b) T2FS intensity changes. DM, deep 
muscles that includes flexor hallucis longus and flexor digitorium longus; Gas_L, gastricnemius lateral head; Gas_M, gastricnemius medial head; PL+, 
peroneus longus, peroneus brevis, and peroneus tertius; Sol, soleus muscle; TA+, tibialis anterior, extensor hallucis longus, and extensor digitorum 
longus; T2FS, T2-weighted fat-saturation.
Figure 3 examples of axial view of t2Fs images at mid-calf level of preperfusion. (a) postperfusion (b) and postperfusion with manual segmen-
tation (c) for subject 06. Yellow arrows: muscles with severe degenerative changes. DM, deep muscles that includes flexor hallucis longus and flexor 
digitorium longus; Gas_L, gastricnemius lateral head; Gas_M, gastrocnemius medial head; PL+, peroneus longus, peroneus brevis, and peroneus 
tertius; Sol, soleus muscle; TA+, tibialis anterior, extensor hallucis longus, and extensor digitorum longus; T2FS, T2-weighted fat-saturation.
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pain control in this age group of subjects. The large volume infused 
(~1 liter) can be delivered in less than 15 minutes, a time frame 
that is well within the established safety time limit of 1.5–2 hours 
of tourniquet time in a Bier block regional anesthesia.17 The rate of 
infusion used in this study was up to 80 ml/minute which is compa-
rable to that used in large animal studies of 60–120 ml/minute.18–20 In 
contrast to arterial limb perfusion methods, no surgical procedure 
such as femoral artery catheterization or cutdown is necessary.21
With the infusion parameters used, there were no detectable 
regional injury to the arteries, veins, muscles or nerves in the limb nor 
were systemic cardiac or renal toxicity observed. Subjects recovered 
within 4 hours and were discharged home. Furthermore, a phone 
follow-up in 2 weeks revealed no self-reported concerns of the sub-
jects. Although the compartment pressures in subject 05 were ini-
tially high, the pressures in all three compartments steadily returned 
to below threshold level without any intervention, and there was no 
evidence of tissue damage related to the transient elevation of com-
partment pressure. For the two subjects (06 and 07) who had muscle 
MRI, the majority of muscles had marked volume enlargement. The 
muscles in posterior compartment, the largest compartment, had the 
most muscle volume enlargement and most T2FS intensity increase 
(Figure 4). This correlated with the observation that the posterior 
compartment had the greatest pressure increases during perfusion 
(Figure 2a). In primate studies, increased T2FS signal was associ-
ated with gene expression.18 It has been postulated that postcapillary 
venules may be the site of fluid entry into the muscle.22,23
Our study is limited by the small number of subjects. We 
noticed variations in the compartmental pressure in the three 
subjects who received 20% of limb volume perfusions. It was not 
certain why it took 05 longer to recover compartment pressures 
to normal. However, this subject was a very slim individual with 
a body mass index of 19. It is likely that this subject had relatively 
less expandable soft tissues (muscles and subcutaneous tissue) in 
proportion to nonexpandable tissue (bones); thus 20% limb per-
fusion may have been a relatively higher perfusion volume relative 
to soft tissue volume compared to the other subjects.
The maximum fluid volume that we used was 20% of the per-
fused limb segment volume. This volume is similar to that used 
for whole pelvic limb perfusion in dogs with the AAV-mini-
dystrophin construct which has produced robust mini-dystro-
phin expression.20 The typical dose in dogs is 15–20 ml/kg of body 
weight. Subjects 05–07 in our study received 12–15 ml/kg but this 
entire volume was perfused below the knee.
In conclusion, high-pressure retrograde transvenous perfu-
sion of the lower extremity with 0.9% saline up to 20% of limb 
volume at the employed infusion parameters is safe and feasible in 
human muscular dystrophy. This trial serves as a basis for future 
human gene transfer clinical trials as a method of regionally deliv-
ering macromolecular therapeutics, such as gene transfer, in high 
doses to skeletal muscles.
MAterIAls And MetHods
Study subjects. Study inclusion criteria were: biopsy-confirmed or mutation 
proven Becker muscular dystrophy or other clinically diagnosed muscular 
dystrophies (including LGMD or EDMD), ability to stand for minimum of 
10 minutes and to give informed consent. Exclusion criteria included posi-
tive pregnancy test, evidence of cardiomyopathy, pulmonary insufficiency, 
renal insufficiency, history of local injury to lower extremities such as neu-
ropathy, vascular injury (including arterial or venous thrombosis), surgery, 
trauma, or compartment syndrome. The study was approved by the Office 
of Research Ethics of the University of North Carolina at Chapel Hill (IRB). 
Written informed consent was obtained from each subject. This study is 
registered on ClinicalTrials.gov with an identifier of NCT00873782.
Preperfusion and postperfusion studies. Outpatient preperfusion and post-
perfusion visits within 1 week of the perfusion include the following tests: 
venous Doppler study to assess venous valvular incompetency or venous 
thrombosis, arterial Doppler study,24 electro-diagnostic testing using stan-
dard neurographic techniques of three nerves in lower extremities per-
formed in triplicate by the same examiner, quantitative muscle strength 
assessments with a handheld dynamometer (JTechAA104; JTech Medical, 
Salt Lake City, UT) and timed walk25 (performed by licensed physical thera-
pists who are familiar with muscular dystrophy). Preperfusion studies were 
done bilaterally in the lower extremities. postperfusion neurography and 
Doppler studies were only performed in the perfused leg. Also obtained 
at these visits were detailed history, neurological examination, basic meta-
bolic panel (Na+, K+, Cl–, CO2, BUN, and creatinine), CK, plasma and 
urine myoglobin, pregnancy test for women, and limb photos. Limb seg-
mental volume (just above knee) was measured by water immersion.
Perfusion procedure. The subjects were instructed to take no solid food 
after midnight and no liquids after 6 AM. They were admitted to Pediatric 
Intensive Care Unit the morning of the perfusion study. A peripheral 
intravenous catheter was placed in the antecubital vein for blood draws 
and IVA. IVA was administered by a board-certified anesthesiologist with 
a combination of opioids, benzodiazepines, and propofol with monitor-
ing following the American Society of Anesthesiology (ASA) guidelines. 
Blood pressure, heart rate, electrocardiogram, respiratory rate, and pulse 
oximetry were continuously monitored. A Somanetics INVOS near-infra-
red oxygen monitor sensor (Somanetics, Troy, MI) was placed on each calf 
to monitor distal limb tissue oxygenation,26 while a second pulse oximetry 
was placed onto the toe of the perfused limb. Basic metabolic panel, CK, 
urine, and serum myoglobin were checked at baseline (preperfusion) and 
hourly postperfusion until the patient was deemed ready for discharge. A 
portable transthoracic echocardiograph (Sonos 5500; Philips Healthcare, 
Andover, MA) was used to assess cardiac systolic function and measure 
systolic and diastolic dimensions. In addition, we continuously observed 
for microcavitation in the right atrium during infusion which would indi-
cate saline leak due to loss of cuff occlusion. A lower extremity was chosen 
for the study for each subject. An intravenous catheter (1.5 inches long 
and 18 or 20 gauge) was placed percutaneously in the saphenous vein at 
the ankle. Using the premeasured segmental limb volume and the protocol 
specified perfusion dose, the volume of normal 0.9% saline to be infused 
as a percent of the segmental limb volume was determined. A pneumatic 
tourniquet (ATS 2000; Zimmer, Warsaw, IN) was placed above the knee 
at the line marked during limb volume measurements at the preperfusion 
visit. The inflation pressure was set to 310 mm Hg and tested briefly while 
the subject was awake. This is the pressure recommended for intravenous 
regional anesthesia.27 Saline was infused with an FMS 2000 Rapid Infuser 
(Belmont Instrument, Billerica, MA).28 The infusion rate was set at 60 ml/
minute in the first subject and increased to 80 ml/minute for the others. 
The Belmont FMS 2000 Rapid Infuser will infuse to a maximum line pres-
sure of 300 mm Hg. When a line pressure of 300 mm Hg is reached, the 
infusion rate is automatically decreased. Following completion of the infu-
sion, the tourniquet remained inflated for 1 minute and was then deflated. 
Photos of the limb were taken before, during and after perfusion.
We measured pressures in three muscle compartments (anterior, 
lateral, and posterior) of the perfused limb in all subjects immediately 
after the tourniquet was released to evaluate for compartment syndrome. 
For the first five subjects, we used spot checks that required multiple 
needle punctures. For the last two subjects, we employed continuous 
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monitoring by indwelling catheters (Indwelling Slit Catheter; Stryker 
Surgical, Kalamazoo, MI) before, during, and after the perfusion until the 
pressures returned to less than 35 mm Hg.
Safety boundaries. Safety boundaries were set conservatively in anticipa-
tion that these changes may not be clinically significant but may predict 
problems at the next higher dose. The safety boundaries for limb tissue 
oximetry (<31%) and compartment pressures (>35 mm Hg) were based 
on a study of chronic exertional compartment syndrome with transient 
pain during exercise without muscle damage, not traumatic compartment 
syndrome.26 For electro-diagnostic nerve testing, the postperfusion ver-
sus preperfusion changes was set to >1 msec for the distal motor latency, 
<75% of CMAP or sensory nerve action potential amplitude and velocity. 
Cardiac function and dimension were to remain within 90% of baseline. 
Quantitative muscle testing and timed walking were set to be within 85% 
baseline. Venous Doppler was used to evaluate for new valvular incompe-
tence or thrombosis and arterial Doppler to detect stenosis. For laboratory 
values, we set criteria for serum creatinine of >0.5 mg/dl over baseline, 
and for serum potassium of >0.5 mmol/l over baseline or >5.0 mmol/l. We 
did not specify the safety boundary for CK, urine and serum myoglobin, 
as ascribing clinical significance to specific values with high baseline val-
ues and underlying muscle disease is problematic.
Safety monitoring. A Local Independent Safety Monitor reviewed the 
safety report prepared after the completion of each subject’s study and 
approved the infusion parameters for the next subject.
An external independent Safety Officer was appointed by National 
Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). 
Biannual safety reports were submitted via KAI Research (Rockville, MD).
MRI acquisition and data analysis. The final two subjects underwent 
T2FS MRI scan at baseline and immediately postperfusion to determine 
the distribution of fluid entry in the muscles. Images were acquired using 
a 3T Trio MR system (Siemens Medical, Erlangen, Germany) with a maxi-
mal gradient strength of 40 mT/m and a maximal slew rate of 200 mT/m/
ms. A phase array body coil was used to acquire data. A turbo spin echo 
with variable flip angle sequence was utilized to acquire 3D high resolu-
tion T2 weighted images. The imaging parameters were set as follows: TR/
TE = 2,500/390 msec, field of view (FOV) = 400 × 400 × 112 mm3, matrix 
size = 384 × 384 × 112, resulting in a nearly isotropic voxel size of 1 × 1 × 
1 mm3; 38.5% oversampling in the slice select direction; fat saturation; two 
averages; total data acquisition time = 11 minutes 42 seconds.
T2FS images were manually segmented into several groups of muscles 
in whole muscle length using open source software ITK-SNAP 2.0 (ref. 29) 
(www.itksnap.org). The preperfusion and postperfusion images were 
aligned using the tibial bone as landmark. Volumetric data and T2FS 
intensity data were obtained after the segmentation was finalized. The 
average signal intensity from the whole length of the peroneus muscles 
in the control leg was used to normalize the signal intensities of the 
preperfusion and postperfusion scans.
suPPleMentArY MAterIAl
Table S1. Summary of demographics of study subjects and testing 
results.
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